EMA Authorised: Tecvayli (teclistamab) — Janssen-Cilag International N.V.

View source ↗

Summary

The European Medicines Agency authorised Tecvayli (teclistamab) for the treatment of multiple myeloma. The approval is conditional.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Janssen-Cilag International N.V.. Decision date: 12/06/2025. Conditional approval